Office Action Predictor
Application No. 17/927,420

ADENOVIRUS FOR ANTI-TUMOUR THERAPY

Non-Final OA
Filed
Nov 23, 2022
Examiner
LI, RUIXIANG
Art Unit
1674
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Medizinische Hochschule Hannover
OA Round
1 (Non-Final)
59%
Grant Probability
Moderate
1-2
OA Rounds
2y 10m
To Grant
70%
With Interview

Examiner Intelligence

59%
Career Allow Rate
602 granted / 1015 resolved
Without
With
+10.3%
Interview Lift
avg trend
2y 10m
Avg Prosecution
28 pending
1043
Total Applications
career history

Statute-Specific Performance

§101
1.4%
-38.6% vs TC avg
§103
25.8%
-14.2% vs TC avg
§102
15.9%
-24.1% vs TC avg
§112
34.8%
-5.2% vs TC avg
Black line = Tech Center average estimate • Based on career data

Prosecution Timeline

Nov 23, 2022
Application Filed
Apr 02, 2026
Non-Final Rejection (current)

Precedent Cases

Applications granted by this same examiner with similar technology. Study what changed to get past this examiner.

Patent 12589150
ANTIBODIES BINDING AXL
2y 5m to grant Granted Mar 31, 2026
Patent 12583921
TARGETED ANTI-SGLT1 AVIAN IGY ANTIBODIES AS TREATMENT OF PRE-DIABETES, TYPE 2 DIABETES AND GESTATIONAL DIABETES
2y 5m to grant Granted Mar 24, 2026
Patent 12577307
METHOD AND MEDICAMENT FOR TREATING CANCER UNRESPONSIVE TO PD-1/PD-L1 SIGNALING INHIBITOR
2y 5m to grant Granted Mar 17, 2026
Patent 12578337
METHOD FOR PROGNOSIS PREDICTION OF SKIN CANCER AND USE THEREOF
2y 5m to grant Granted Mar 17, 2026
Patent 12569497
USE OF HCN INHIBITORS FOR TREATMENT OF CANCER
2y 5m to grant Granted Mar 10, 2026

AI Strategy Recommendation

Click below to generate an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
59%
Grant Probability
70%
With Interview (+10.3%)
2y 10m
Median Time to Grant
Low
PTA Risk
Based on 1015 resolved cases by this examiner